Ribonucleotide reductase has a crucial role in de novo DNA synthesis by reducing NDPs to 2′-dNDPs 1 and maintains balanced pools of dNTPs in the cell 2 . RRs are divided into three classes, I-III, on the basis of the method of free-radical generation [3] [4] [5] [6] [7] [8] . All eukaryotic organisms encode a class I RR, composed of an α n β n multisubunit protein complex whose minimally active form is α 2 β 2 (refs. 9,10). The α or RR1 subunit contains the catalytic site (C site) and two allosteric sites 11 , whereas the β or RR2 subunit houses a stable tyrosyl free radical that is transferred ~35 Å to the catalytic site to initiate radical-based chemistry on the substrate 12,13 . In yeast, β 2 is ββ′, which denotes the RR2-RR4 heterodimer: RR2 is a functional β subunit, whereas RR4 (β′) lacks key residues required for producing the free radical. RR is regulated transcriptionally 14 , allosterically 1 and, in the yeast Saccharomyces cerevisiae, RR is further regulated by subunit localization 15 and by its protein inhibitor Sml1 (ref. 16). In mammalian cells, RR activity is also controlled by RR2 levels 17, 18 . Consistent with varying RR2 levels, dNTP pools also vary with the phases of the cell cycle, reaching the highest concentration during S-phase of the cell cycle 17, 19 .
To assess the similarity of hRRM1 to its class I and II homologs, we aligned the structures of RR1 from S. cerevisiae (ScRR1), E. coli (EcRR1), Thermotoga maritima (TmNrd1) and Salmonella typhimurium (StRR1) with all four structures of the hRRM1 complexes in a pairwise fashion (Supplementary Table 1 ). hRRM1 shares the highest structural homology with ScRR1, with an r.m.s. deviation of 0.8 Å, whereas EcRR1, TmNrd1 and StRR1 have r.m.s. deviations of 1.4 Å, 1.3 Å and 1.3 Å, respectively. A full comparison and description of the C and S sites are in Supplementary Discussion.
Allosteric regulation at the activity site dATP functions as an allosteric inhibitor by having higher affinity for the A site than ATP 23, 25 . Hence, dATP outcompetes ATP, which is more abundant in the cell than dATP. Compared with ATP, dATP binds the A site with a ~13-fold and 40-100-fold higher K d for EcRR1 and mRR1, respectively 23, 25 . The structural basis for why dATP functions as an The four-helix cone with ATP bound. 2F o -F c electron density for ATP (carbon, oxygen and nitrogen atoms are yellow, red and blue, respectively) contoured at 1 σ is in green wire mesh. (c) The four-helix cone with dATP bound. 2F o -F c electron density for dATP (carbon, oxygen and nitrogen atoms are black, red and blue, respectively) contoured at 1 σ is in blue wire mesh. Table 1 Data collection and refinement statistics (molecular replacement)
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Space group P 2 1 a r t i c l e s inhibitor and ATP as an activator has been unknown. We have now determined structures of hRRM1 with ATP or dATP bound at the A site (Figs. 1b,c and 2a,b) . The A site is formed by helices H1-H4, with H1 spanning residues 15-26, H2 spanning residues 36-46, H3 spanning residues 53-70, and H4 spanning residues 74-90 (Fig. 2c) ; the helices form a four-helix bundle. This ATP-binding cone is covered at one end by the previously named "β-cap, " a β-hairpin formed by the first 14 N-terminal residues and residues 48-51 (ref. 10) . Although binding of both ATP and dATP requires helix H1 and the β-cap to shift from their positions in the native (TTP-only) form (Fig. 2c) , leading to some induced fit, the two binding modes are markedly different. dATP binds more deeply inside the four-helix bundle and its ribose adopts a half-chair conformation with the C2′ out of plane. In contrast, ATP binds less deeply inside the four-helix bundle and its ribose adopts a 2′-endo conformation (Fig. 2c,d and Supplementary Fig. 1a) . The distance between the positions of the 3′-OH of ATP and dATP is 2.4 Å (Fig. 2d) . We used the program DPX 35 to calculate the atomic depth, the distance from the closest solvent accessible atom, and found that dATP has a depth of 1.53 Å whereas ATP has a shallower depth of 1.33 Å. Furthermore, surface accessibility calculations with AREAIMOL 36 show that upon binding to the A site ATP buries 297 Å 2 , whereas dATP buries 310 Å 2 . Because the binding energy of protein-ligand interactions can be expressed as a change in solvent-accessible surface area between the bound and unbound states 37 , the deeper binding of dATP and the larger buried surface area compared with ATP must contribute to its higher affinity.
The different ribose conformations in the bound ATP and dATP molecules may further contribute to their affinities for the A site.
The chemical difference at the 2′ position on the ribose moiety between ATP and dATP causes the difference in their binding at the A site. The 2′-OH of ATP sterically precludes the ribose from binding more deeply inside the four-helix bundle, whereas dATP, lacking the 2′-OH, can penetrate the pocket more deeply. We propose that Ile18 acts as a steric gate, as it would clash with the 2′-OH of ATP binding at the dATP position ( Fig. 2d and Supplementary Fig. 1a ). The C2′ of the ribose in dATP makes several interactions with hydrophobic residues (Fig. 2b and Supplementary Table 2) . Notably, whereas the 3′-OH of dATP makes no hydrogen bonds with hRRM1, the 3′-OH of ATP makes a hydrogen bond with the side chain of Asp57. The D57N mutation abolishes the ability of hRRM1 to discriminate between ATP and dATP at the A site 38 . In our ATP-bound structure, Asp57 forms a salt bridge with Arg21, which interacts with both the phosphate and ribose moieties (Fig. 2a) . The D57N mutation probably abolishes the salt bridge and changes the electrostatic environment of the A site. The resulting loss of allosteric regulation by dATP is discussed below under dATP-induced oligomerization.
The phosphate groups of dATP and ATP bound at the A site adopt different conformations (Fig. 2c,d) . The phosphate moiety of bound ATP is held in place by a ring of positively charged residues (Lys5, Arg6, Lys17, Arg21 and Lys88; Fig. 2a) . We also observe two magnesium ions interacting with the negatively charged phosphate groups in the ATP-bound structure, which appear to be absent in the dATP-bound form (Fig. 2a,b) . In contrast to ATP bound at the A site, the phosphate groups of bound dATP are extended rather than folded back to place the γ-phosphate close to the adenine ring, and Lys17 no longer interacts with the γ-phosphate (Fig. 2a,d) . However, the difference in phosphate conformations between ATP and dATP bound at the A site may be partly due to the absence of magnesium binding in the dATP structure.
The adenine ring in dATP binds more deeply in the nucleotidebinding pocket than that in ATP. As a consequence, unlike ATP, dATP is not within hydrogen-bonding distance of the side chain atoms of the surface residues Lys5 and Glu11. Conversely, the amide nitrogen of Met14 hydrogen-bonds with the adenine base of dATP, an interaction not observed in the ATP-bound structure (Fig. 2a,b) . Both bases form hydrophobic interactions with Val3, Ile18 and Leu56, which pack against both faces of the adenine ring (for clarity Leu56 is not shown in Fig. 2a,b) .
The only other RR1 structure with an effector bound at the A site currently available is that of EcRR1 containing the bound ATP analog AMPPNP 39 (Supplementary Fig. 1b) . The adenine base of AMPPNP occupies a different position in EcRR1 than that of ATP in hRRM1 (Supplementary Fig. 1b) . We attribute the differences in binding to a r t i c l e s (i) different conformations of the β-cap, (ii) displacement of the β-cap in EcRR1 toward solvent by at least 6 Å and (iii) the N-terminal portion of helix H1 in the EcRR1 structure protruding toward the ribose, in contrast with its position in the hRRM1 structure.
dATP-induced oligomerization
We examined the dATP concentration-dependent oligomerization of wild-type and mutant hRRM1 using size-exclusion chromatography (SEC) and multiangle light scattering (MALS) ( Fig. 3 and Supplementary Fig. 2 ). Our measurements show that without any effector molecules, hRRM1 is a monomer (Fig. 3a, blue line) . Notably, at a dATP concentration of 5 µM, we observed a reduction in monomers with concomitant emergence of dimers and hexamers (Fig. 3a , red line). At a dATP concentration of 20 µM, within the reported concentrations for S-phase 17, 19 , the hexamer dominated and fewer dimers were present (Fig. 3a, green line) . We independently corroborated these results using MALS (Supplementary Fig. 2a ). At 20 µM dATP, MALS showed peaks at 521 kDa and 185 kDa corresponding to an hRRM1 hexamer and dimer, respectively. Similar observations have been reported for mouse RR1 (ref. 31) . Notably, when the first 74 residues of hRRM1 belonging to the ATP-binding cone were deleted (t-hRRM1), dATP no longer induced the formation of hexamers. Instead, in the presence of hRRM2, dATP induced the formation of an α 2 β 2 holo human RR complex. This result further shows the importance of the A site for oligomerization (Fig. 3c) .
We assessed the activity of the dATP-induced oligomers through in vitro functional assays. In the first assay we measured the rate of dCDP formation using [ 3 H]CDP as the substrate and ATP as the effector 33 . In the second assay we used [ 14 C]ADP as the substrate and dGTP and ATP as the effectors. The specific activities of hRR and yeast RR are in Table 2 . At increasing concentrations of dATP, at which hRRM1 exists mainly as a hexamer, the specific activity of hRRM1 diminished (Supplementary Fig. 2b ). We observed similar results for yeast RR (Supplementary Fig. 2c ).
These findings deviate from previous studies reporting that the dATP tetramer is the least active RR form and that the hexamer is observed only at nonphysiologically high dATP concentrations 23 . This discrepancy may not be due to the results obtained by dynamic light scattering but rather to their interpretation. Because dynamic light scattering experiments on mixtures of oligomeric species cannot resolve differences in radius that are less than a factor of 4-5 in magnitude, the reported value may have been the average mass of all the species in solution. Therefore, the measured value of ~380 kDa in the presence of 10-100 µM dATP 23 may not represent an RR tetramer but rather a mixture of dimers and hexamers.
X-ray crystal structure of the ScRR1-dATP hexamer To clarify the structural basis of RR1 oligomerization, we worked on crystallizing hRRM1 α 6 . Although dATP-induced hexamers of hRRM1 crystallized in a hexagonal space group, the crystals only diffracted to a resolution of 10 Å. However, we obtained crystals of dATP-induced hexamers of ScRR1 in the P6 3 space group that diffracted to 6 Å ( Table 1) . We expect that the ScRR1 hexamer is similar to the hRRM1 hexamer as they both form mainly inactive hexamers at 20 µM dATP (Fig. 3a and Supplementary Fig. 2d) , and the structures of the dimers are similar (Supplementary Table 1) . We determined a low-resolution structure of the ScRR1-dATP hexamer using molecular replacement. Because no structure exists of a ScRR1 with dATP bound at the A site, we used the hRRM1-TTP-dATP structure (Fig. 1a) as the search model for molecular replacement. Rigidbody refinement at 6.6 Å gave an R free of 44.3% (Table 1) , which, at this resolution, indicates a correct solution. Although low-resolution structures do not provide details at the atomic level, they are useful in considering oligomer organization.
The packing of the ScRR1 subunits in the crystal is consistent with two different hexamer models, which we call models A and B (Fig. 4a,b) . Multiple crystal packing arrangements are not uncommon, so it is necessary to identify the physiologically relevant one. In both models, the ScRR1 α 6 is a trimer of dimers, in which the three dimers are related to each other by a three-fold axis. However, models A and B differ in the diameter of the central pore of the hexamer and in how dATP would mediate hexamerization. In model A, only three a r t i c l e s of the six dATP-bound four-helix ATP-binding cones participate in forming the hexamer interface, leaving the other three free to interact with the small subunit (Fig. 4a,c) . Hence, only three dATP molecules are at the hexamer interfaces. In contrast with model A, in model B the interfaces between the dimers that stabilize the hexamer are exclusively formed by the six dATP-bound four-helix ATP-binding cones (Fig. 4b) . Each of the three interfaces is formed by two dATP-bound four-helix cones from adjacent RR1 dimers that contact each other in an antiparallel conformation and are related by two-fold symmetry.
Validation of the dATP-induced hexamer mutagenesis
We inspected the hexamer interfaces in both models for interactions that could be targeted by mutagenesis to disrupt hexamerization. We designed several site-directed mutations on the basis of the interface in model B, but with the exception of D16R and H2E ( Supplementary  Fig. 3a) , mutations in the N-terminal ATP-binding cone led to insoluble protein. Packing interactions in model A are poor compared with model B, and we chose a single mutation, D182R, to test this model. Using SEC, we tested each mutant for its ability to form hexamers at the approximate S-phase concentration of 20 µM dATP. As we observed earlier, most of the wild-type protein formed hexamers at this dATP concentration (Fig. 3d, green trace) . The H2E mutation led to a shift of the equilibrium from mainly hexamer with little dimer to more dimer and less hexamer, whereas the D16R mutation disrupted hexamer formation completely (Fig. 3d, orange and purple traces). The molecular masses of the oligomers formed by the D16R mutant protein were independently derived from MALS to be 190 kDa and 88 kDa, corresponding to a dimer and monomer, respectively (Supplementary Fig. 2e ). To further confirm that Asp16 was involved in hexamerization, we also examined the D16R mutation in ScRR1. As we expected, ScRR1 D16R mutant protein also did not form dATP-induced hexamers (data not shown), indicating that the same mechanism must underlie dATP-induced hexamerization of ScRR1 and hRRM1. Notably, the aforementioned D57N mutant, which is not inhibited by dATP, also forms dimers but not hexamers at physiological concentrations (Supplementary Fig. 3b ) 40 . The D182R mutation at the hexamer interface according to model A in ScRR1 did not disrupt dATP-induced hexamerization (data not shown).
Because the D16R mutation abolished the ability of hRRM1 to form dATP-induced hexamers, we hypothesized that D16R, like D57N, would prevent allosteric inhibition of hRRM1 by dATP at physiological concentrations. To test this hypothesis, we subjected purified wildtype, D16R and H2E proteins to in vitro activity assays using [ 3 H]CDP and [ 14 C]ADP as substrates. The D16R and H2E mutant proteins retained 55% and 56% of the wild-type activity for CDP reduction and 67% and 56% of the wild-type activity for ADP reduction, respectively (Fig. 3e) . The D16R mutant has similar activities in the presence and absence of 20 µM dATP (Fig. 3f) . Furthermore, CD spectroscopy showed that all mutants were properly folded ( Supplementary  Fig. 3c) , and isothermal titration calorimetry showed that the D16R protein retained its ability to bind dATP (data not shown). Because the D16R and D57N mutants are not inhibited and do not form hexamers at physiologically relevant dATP concentrations, these results confirm that allosteric inhibition of RR by dATP under physiological conditions requires hRRM1 to be in a hexameric form.
SEC, MALS and in vitro activity assays provide experimental evidence that the dATP-induced hexamer in solution takes the form of model B (Fig. 4b) . Only site-directed mutations designed based on model B, but not model A, interfered with hexamer formation. To test whether mutants interfering with dATP-induced hexamerization also disrupt the interface needed for ATP-induced oligomerization, we conducted SEC analysis of the mutants in the presence of ATP. The D16R mutant, which was specifically designed to disrupt the dATP hexamer, retained its ability to form hexamers in the presence of ATP (Supplementary Fig. 3d) . The H2E and D57N mutants could also form ATP hexamers (data not shown). Furthermore, we found that wild-type and mutant hRRM1 are similar in their apparent dissociation constant, K d(app) , for ATP binding (Supplementary Fig. 3d ).
Modeling and EM reconstruction of the ScRR holocomplex
To further examine how hexamer models A and B fit with published data, we carried out modeling studies using the previously determined crystal structure of the StRR1-StRR2 α 2 β 2 holocomplex 30 (see Supplementary Methods). In the case of model A, the ScRR2 subunits would bind to the outside of ScRR1-dATP α 6 , allowing up a r t i c l e s to six ScRR2 subunits to bind to ScRR1-dATP α 6 and, hence, permitting the formation of α 6 β 2 , α 6 β 4 and α 6 β 6 complexes (Fig. 4c) . In the case of model B, the ScRR2 subunits bind in the central cavity of ScRR1-dATP α 6 , which is only large enough to accommodate two small yeast RR subunits. Therefore, the dATP-induced holocomplex could only be α 6 β 2 (Fig. 4d) .
We isolated the ScRR-dATP holocomplex using SEC. The molecular mass derived from SEC was consistent with an α 6 ββ′ complex (Supplementary Fig. 4) . EM images of the purified yeast RR-dATP holocomplex in negative stain showed a homogeneous particle population (Fig. 5a) , and class averages (Fig. 5a, small panels) showed particles with well-defined features consistent with different views of the holocomplex (see Supplementary Methods). A 3D reconstruction of the holocomplex in cryonegative stain was then calculated using 50°/0° tilt pair images and the random conical tilt approach 41 (see Supplementary Methods for details). The density map at a resolution of 28 Å (Fig. 5b) could be used to fit in the X-ray structures of the ScRR1-dATP hexamer and the ScRR2-ScRR4 heterodimer (Fig. 5c) . The resulting model of the holocomplex is consistent with an α 6 ββ′ complex and, as the ScRR2-ScRR4 heterodimer is clearly located inside the ring formed by ScRR1-dATP α 6 , supports model B for the hexameric arrangement of ScRR1.
DISCUSSION
On the basis of structure-function data, we present a model that accounts for the downregulation of RR activity by dATP-induced oligomerization (Fig. 5d) . Our SEC and MALS data show that there is a dynamic equilibrium between the α, α 2 and α 6 forms of hRRM1 and that the hexamer population increases with increasing dATP concentrations 31 (Fig. 3a and Supplementary Fig. 2a) . Without nucleotide effectors, RR1 exists as an inactive monomer. Binding of the effectors ATP, dATP, TTP or dGTP to the S site causes RR1 to form dimers, which can then form α 2 β 2 heterotetramers. Partial occupation of the A site by dATP may cause two α 2 subunits to associate into a transient tetramer intermediate that is not observable in our SEC and MALS experiments. This is presumably because once the S site is occupied by NTP effectors and the α 2 subunit is formed, higher-order oligomerization will occur by the association of sets of RR1 dimers rather than monomers with dimers. Hence, transient tetramers may be formed by the association of two RR1 dimers. The tetramers may be very unstable, and either fall apart again or immediately pick up an additional dimer to form a hexamer, making them difficult to observe. However, we cannot rule out the possibility that three dimers may associate to form a hexamer without the requirement of a tetramer. RR activity will also continue to diminish with the increase in dATPinduced hexamers in response to increased dATP levels. Consistent with previous data 31 and our EM structure, α 6 can associate with β to form an α 6 β 2 holocomplex in the presence of dATP. Finally, when dATP levels become depleted during DNA replication or repair, dATP will dissociate from the A site and active ATP-bound RR oligomers will be formed to replenish the dNTP supply.
Several groups have reported data on the quaternary structure of mammalian RRs, including an α 6 β 2 complex for both ATP and dATP 31 , as well as ATP-induced α 6 β 6 holocomplexes 23, 33 . The structure of the yeast RR-dATP holocomplex shows that only a dimer of the small subunit can be accommodated inside the hexamer pore, forming an α 6 β 2 complex (Fig. 5c) . As both ATP and dATP can form hexamers, how can dATP be an allosteric inhibitor while ATP is an allosteric activator? Our SEC data on the mutants suggest that dATP and ATP form different types of hRRM1 hexamers. If the ATP and dATP hexamers have different packing arrangements, as our data suggest, this may offer clues to why ATP and dATP exert opposite allosteric effects on RR. The conformational changes accompanying dATP hexamerization may lead to the disruption of free-radical transfer to the active site. Indeed, although a higher-resolution structure will be needed to be certain, our low-resolution model of the yeast RR holocomplex indicates that the small subunit (ScRR2-ScRR4) may bind farther away from ScRR1 ( Supplementary Fig. 5 ) compared with the StRR holocomplex, which is considered to be an intermediate of the active form. The packing of the RR-ATP holocomplex, on the other hand, may only lead to conformational changes that promote the activation of RR.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
